Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

被引：0
|
作者：
Lucia Del Mastro
Alessandra Fabi
Mauro Mansutti
Michele De Laurentiis
Antonio Durando
Domenico Franco Merlo
Paolo Bruzzi
Ignazia La Torre
Matteo Ceccarelli
Gbenga Kazeem
Paolo Marchi
Davide Boy
Marco Venturini
Sabino De Placido
Francesco Cognetti
机构：
[1] UO Sviluppo Terapie Innovative,IRCCS AOU San Martino
[2] Regina Elena Institute, IST
[3] S. Maria della Misericordia Hospital, National Institute for Cancer Research
[4] University of Naples Federico II,Division Oncology
[5] National Cancer Institute “Fondazione Pascale”,Department Oncology
[6] A.O.O.I. Regina Margherita S. Anna,Department of Endocrinology and Molecular and Clinical Oncology
[7] UO Epidemiologia Clinica,Department of Senology, Division of Breast Oncology
[8] Medical Department,IRCCS AOU San Martino
[9] Eli Lilly UK, IST
[10] S. Cuore – Don Calabria Hospital, National Institute for Cancer Research
来源：
BMC Cancer | / 13卷
关键词：
Metastatic breast cancer; Weekly schedule; 3-weekly schedule;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer:: Results of a multicenter phase II study
    Palmeri, S
    Vaglica, M
    Spada, S
    Filippelli, G
    Farris, A
    Palmeri, L
    Massidda, B
    Misino, A
    Ferraù, F
    Comella, G
    Leonardi, V
    Condemi, G
    Mangiameli, A
    De Cataldis, G
    Macaluso, MC
    Cajozzoo, M
    Iannitto, E
    Danova, M
    ONCOLOGY, 2005, 68 (4-6) : 438 - 445
  • [12] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
  • [13] Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer
    O'Shaughnessy, Joyce A.
    Pluenneke, Robert
    Sternberg, Jack
    Khandelwal, Pankaj
    Ilegbodu, Des
    Asmar, Lina
    CLINICAL BREAST CANCER, 2006, 6 (06) : 505 - 510
  • [14] Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial
    Boccia, R. V.
    Vaughn, L.
    Zeigler, H.
    Wang, Y.
    Gill, J.
    Melemed, A.
    Shonukan, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [15] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    British Journal of Cancer, 2004, 90 : 31 - 35
  • [16] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [17] Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
    Takashima, Tsutomu
    Mukai, Hirofumi
    Hara, Fumikata
    Matsubara, Nobuaki
    Saito, Tsuyoshi
    Takano, Toshimi
    Park, Youngjin
    Toyama, Tatsuya
    Hozumi, Yasuo
    Tsurutani, Junji
    Imoto, Shigeru
    Watanabe, Takanori
    Sagara, Yoshiaki
    Nishimura, Reiki
    Shimozuma, Kojiro
    Ohashi, Yasuo
    LANCET ONCOLOGY, 2016, 17 (01): : 90 - 98
  • [18] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Iglesias, J
    Melemed, A
    ONCOLOGY, 2002, 62 (01) : 2 - 8
  • [19] Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    Binghe Xu
    Zefei Jiang
    Sung-Bae Kim
    Shiying Yu
    Jifeng Feng
    Artur Malzyner
    Auro del Giglio
    Hyun C. Chung
    Li Jun Shen
    Daniel Lee Kay Pen
    Breast Cancer, 2011, 18 : 203 - 212
  • [20] Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
    Gligorov, Joseph
    Doval, Dinesh
    Bines, Jose
    Alba, Emilio
    Cortes, Paulo
    Pierga, Jean-Yves
    Gupta, Vineet
    Costa, Romulo
    Srock, Stefanie
    de Ducla, Sabine
    Freudensprung, Ulrich
    Mustacchi, Giorgio
    LANCET ONCOLOGY, 2014, 15 (12): : 1351 - 1360
12345